Cancer Vaccines Market Worth US$ 10.72 Billion by 2027 | CAGR of 11.70% | IMARC Group

According to IMARC Group's latest report, titled "𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗧𝗿𝗲𝗻𝗱𝘀, 𝗦𝗵𝗮𝗿𝗲, 𝗦𝗶𝘇𝗲, 𝗚𝗿𝗼𝘄𝘁𝗵, 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗮𝗻𝗱 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 2022-2027", the cancer vaccines market reached US$ 5.43 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.72 Billion by 2027, exhibiting a CAGR of 11.70% during 2022-2027.

Cancer refers to a malignant tumor caused by the uncontrollable growth of abnormal cells in the body. It can be treated through the use of numerous medications and vaccines. Among these, vaccinations are broadly classified into preventive and therapeutic. Preventive cancer vaccines are deployed to eliminate the tumor generated by oncovirus and protect from human papillomavirus (HPV), whereas therapeutic vaccinations aid in stimulating the individual adaptive immune systems by using tumor antigens. Presently, these vaccines are commercially available in varying types, such as antigen, dendritic cells, and anti-idiotype.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗳𝗿𝗲𝗲 𝘀𝗮𝗺𝗽𝗹𝗲 𝗯𝗿𝗼𝗰𝗵𝘂𝗿𝗲: https://www.imarcgroup.com/cancer-vaccines-market/requestsample

𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬

The growing prevalence of the tumor, on account of the increasing consumption of tobacco-based products and evolving lifestyles of the masses, is primarily augmenting the cancer vaccines market. Furthermore, the launch of favorable initiatives undertaken by the government bodies of several countries for introducing novel cancer vaccinations and various investments in the field of recombinant viral immunization are positively influencing the global market.

Apart from this, the rising utilization of United States Food and Drug Administration (US FDA) approved boosters, including the human papillomavirus vaccine (HPV) and hepatitis B vaccine (HBV), to reduce the risk of certain types of cancer, such as a liver tumor, is acting as another significant growth-inducing factor. Moreover, the inflating technological advancements that focus on the development of effective and specific cancer treatments are also bolstering the market growth. Besides this, the expanding healthcare infrastructure, the growing geriatric population, who are susceptible to numerous chronic ailments, including cancer, and the increasing consumer awareness regarding the symptoms and the available therapy options are expected to drive the cancer vaccines market in the coming years.

𝗖𝗵𝗲𝗰𝗸𝗼𝘂𝘁 𝗡𝗼𝘄: https://www.imarcgroup.com/checkout?id=5901&method=1

𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 2022-2027 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

The competitive landscape of the cancer vaccines market has been studied in the report with the detailed profiles of the key players operating in the market.

𝗦𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲𝘀𝗲 𝗸𝗲𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲:

Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.

𝗞𝗲𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

The report has segmented the cancer vaccines market bases on Type, Technology, Indication And End User.

𝐁𝐫𝐞𝐚𝐤𝐮𝐩 𝐛𝐲 𝐓𝐲𝐩𝐞:

Preventive Cancer Vaccines
Therapeutic Cancer Vaccines

𝐁𝐫𝐞𝐚𝐤𝐮𝐩 𝐛𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲:

Dendritic Cells Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Whole-cell Cancer Vaccines

𝐁𝐫𝐞𝐚𝐤𝐮𝐩 𝐛𝐲 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧:

Cervical Cancer
Prostate Cancer
Others

𝐁𝐫𝐞𝐚𝐤𝐮𝐩 𝐛𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫:

Pediatrics
Adults

𝐁𝐫𝐞𝐚𝐤𝐮𝐩 𝐛𝐲 𝐑𝐞𝐠𝐢𝐨𝐧:

North America: (United States, Canada)
Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa

𝗔𝘀𝗸 𝗔𝗻𝗮𝗹𝘆𝘀𝘁 𝗳𝗼𝗿 𝟭𝟬% 𝗳𝗿𝗲𝗲 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲𝗱 𝗿𝗲𝗽𝗼𝗿𝘁:
https://www.imarcgroup.com/cancer-vaccines-market

𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁:

• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• Market Trends
• Market Drivers and Success Factors
• Impact of COVID-19
• Value Chain Analysis
• Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝗦:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 |
Europe & Africa: +44-753-713-2163 |
Asia: +91-120-433-0800

𝗔𝗯𝗼𝘂𝘁 𝗨𝘀:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.